MedTrace Logo

Symptom Monitoring Using Patient-Report to Improve Medication Use

NCT06765707 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 225

Last updated 2025-07-24

No results posted yet for this study

Summary

This is an intervention targeting patients at risk for non-adherence to endocrine therapy after primary treatments for hormone-positive breast cancer. In a randomized study, the study team will collect patient-reported symptoms monthly from participants through surveys. Pharmacists who specialize in cancer at the patients' hospital will give patients recommendations to help improve their symptoms and address other barriers so they can continue daily endocrine therapy medications.

Conditions

  • Breast Cancer Early Stage Breast Cancer (Stage 1-3)
  • Endocrine Therapy

Interventions

BEHAVIORAL

Pharmacist delivered symptom monitoring and management

Patients in the intervention phase will receive PRO-based symptom monitoring once a month and pharmacist-led management for problematic symptoms based on routine clinical care recommendations.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Medical College of Wisconsin

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-23
Primary Completion
2028-12-31
Completion
2029-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06765707 on ClinicalTrials.gov